About: Thymosin alpha 1: Biological activities, applications and genetic engineering production

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thymosin alpha 1: Biological activities, applications and genetic engineering production Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Thymosin alpha 1: Biological activities, applications and genetic engineering production
Creator	Li, Juan Wang, Shan Liu, Chun
Source	Elsevier; Medline; PMC
abstract	Abstract Thymosin alpha 1 (Tα1), a 28-amino acid peptide, was first described and characterized from calf thymuses in 1977. This peptide can enhance T-cell, dendritic cell (DC) and antibody responses, modulate cytokines and chemokines production and block steroid-induced apoptosis of thymocytes. Due to its pleiotropic biological activities, Tα1 has gained increasing interest in recent years and has been used for the treatment of various diseases in clinic. Accordingly, there is an increasing need for the production of this peptide. So far, Tα1 used in clinic is synthesized using solid phase peptide synthesis. Here, we summarize the genetic engineering methods to produce Tα1 using prokaryotic or eukaryotic expression systems. The effectiveness of these biological products in increasing the secretion of cytokines and in promoting lymphocyte proliferation were investigated in vitro studies. This opens the possibility for biotechnological production of Tα1 for the research and clinical applications.
has issue date	2010-11-30(xsd:dateTime)
bibo:doi	10.1016/j.peptides.2010.07.026
bibo:pmid	20699109
has license	els-covid
sha1sum (hex)	af8a40ac298182ece4b5f9a2973526a4e72d817f
schema:url	https://doi.org/10.1016/j.peptides.2010.07.026
resource representing a document's title	Thymosin alpha 1: Biological activities, applications and genetic engineering production
has PubMed Central identifier	PMC7115394
has PubMed identifier	20699109
schema:publication	Peptides
resource representing a document's body	covid:af8a40ac298182ece4b5f9a2973526a4e72d817f#body_text
is schema:about of	named entity 'chemokines' named entity 'dendritic cell' named entity 'cytokines' named entity '1977' named entity 'production' named entity 'TREATMENT' named entity 'METHODS' named entity 'BIOLOGICAL' named entity 'PRODUCTION' named entity 'APOPTOSIS' named entity 'USED' named entity 'PROMOTING' named entity 'PEPTIDE SYNTHESIS' named entity 'RECENT' named entity 'CHARACTERIZED' named entity 'ITS' named entity 'THYMOSIN ALPHA 1' named entity 'HERE' named entity 'PROKARYOTIC' named entity 'VARIOUS' named entity 'AMINO ACID' named entity 'FAR' named entity 'THESE' named entity 'ENGINEERING PRODUCTION' named entity 'DESCRIBED' named entity 'TO PRODUCE' named entity 'USING' named entity 'EXPRESSION' named entity 'GENETIC ENGINEERING' named entity 'PEPTIDE' named entity 'STEROID' named entity 'DUE TO' named entity 'BIOLOGICAL' named entity 'APPLICATIONS' named entity 'T-CELL' named entity 'BLOCK' named entity 'RESPONSES' named entity 'SECRETION' named entity 'OPENS' named entity 'ACTIVITIES' named entity 'BIOLOGICAL PRODUCTS' named entity 'CLINICAL' named entity 'THYMOSIN ALPHA 1' named entity 'GENETIC ENGINEERING' named entity 'ACTIVITIES' named entity 'INVESTIGATED' named entity 'SYSTEMS' named entity '90%' named entity 'THYMOCYTES' named entity 'SOLID PHASE' named entity 'INTEREST' named entity 'POSSIBILITY' named entity 'IN VITRO STUDIES' named entity 'NEED FOR' named entity 'EUKARYOTIC' named entity 'CLINIC' named entity 'GAINED' named entity 'A31' named entity 'SYNTHESIZED' named entity 'CYTOKINES' named entity 'DISEASES' named entity 'LYMPHOCYTE PROLIFERATION' named entity 'EFFECTIVENESS' named entity 'INDUCED' named entity 'ENHANCE' named entity 'CHEMOKINES' named entity 'YEARS' named entity 'CALF' named entity 'APPLICATIONS' named entity 'DENDRITIC CELL' named entity 'INCREASING' named entity 'RESEARCH' named entity 'ANTIBODY' named entity 'MODULATE' named entity 'peptide' named entity 'thymocytes' named entity 'Due' named entity 'prokaryotic' named entity 'solid phase peptide synthesis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software